Duska Therapeutics, Inc.'s Development Of Respiratory Drug Vagonixen(TM) Moves Forward With Newly Published Study On ATP Effects In Asthmatic Patients

BALA CYNWYD, Pa.--(BUSINESS WIRE)--Nov. 17, 2005--Duska Therapeutics, Inc. (OTC BB:DSKT) today announced the publication of a clinical research study showing that ATP - adenosine 5'-triphosphate - may play a significant role in asthma symptoms. Duska is developing a proposed drug, Vagonixen(TM), as a novel treatment of airway disorders, including chronic obstructive pulmonary disorder (COPD), asthma and cough that would block a specific cell surface receptor activated by ATP and thereby alleviate symptoms of these disorders.

MORE ON THIS TOPIC